

- disease. *Lancet* 1990; 336: 97-100
27. Bender BS, Bennett R, Laughon BE, Greenough WB 3d, Gaydos C, Sears SD, Forman MS, Bartlett JG: Is *Clostridium difficile* endemic in chronic-care facilities? *Lancet* 1986; 2: 11-13
 28. Johnson S, Gerding DN, Olson MM, Weiler MD, Hughes RA, Clabots CR, Peterson LR: Prospective, controlled study of vinyl glove use to interrupt *Clostridium difficile* nosocomial transmission. *Am J Med* 1990; 88: 137-140
 29. Larson HE, Barclay FE, Honour P, Hill ID: Epidemiology of *Clostridium difficile* in infants. *J Infect Dis* 1982; 146: 727-733
 30. Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, Gao N, Xu YL, Walker WA, LaMont JT: Diminished *Clostridium difficile* toxin A sensitivity in newborn rabbit ileum is associated with decreased toxin A receptor. *J Clin Invest* 1992; 90: 822-829
 31. Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, Silva J Jr: Epidemiology of antibiotic-associated colitis: isolation of *Clostridium difficile* from the hospital environment. *Am J Med* 1981; 70: 906-908
 32. Johnson S, Homann SR, Bettin KM, Quick JN, Clabots CR, Peterson LR, Gerding DN: Treatment of asymptomatic *Clostridium difficile* carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. *Ann Intern Med* 1992; 117: 297-302
 33. Triadafilopoulos G, Hallstone AE: Acute abdomen as the first presentation of pseudomembranous colitis. *Gastroenterology* 1991; 101: 685-691
 34. Doern GV, Coughlin RT, Wu L: Laboratory diagnosis of *Clostridium difficile*-associated gastrointestinal disease: comparison of a monoclonal antibody enzyme immunoassay for toxins A and B with a monoclonal antibody enzyme immunoassay for toxin A only and two cytotoxicity assays. *J Clin Microbiol* 1992; 30: 2042-2046
 35. DiPersio JR, Varga FJ, Conwell DL, Kraft JA, Kozak KJ, Willis DH: Development of a rapid enzyme immunoassay for *Clostridium difficile* toxin A and its use in the diagnosis of *C. difficile*-associated disease. *J Clin Microbiol* 1991; 29: 2724-2730
 36. De Girolami PC, Hanff PA, Eichelberger K, Longhi L, Teresa H, Pratt J, Cheng A, Letourneau JM, Thorne GM: Multicenter evaluation of a new enzyme immunoassay for detection of *Clostridium difficile* enterotoxin A. *J Clin Microbiol* 1992; 30: 1085-1088
 37. Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, Lee JT Jr: Prospective randomised trial of metronidazole versus vancomycin for *Clostridium-difficile*-associated diarrhoea and colitis. *Lancet* 1983; 2: 1043-1046
 38. Bolton RP, Culshaw MA: Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to *Clostridium difficile*. *Gut* 1986; 27: 1169-1172
 39. Young G, McDonald M: Antibiotic-associated colitis: why do patients relapse? *Gastroenterology* 1986; 90: 1098-1099
 40. McFarland LV, Surawicz CM, Rubin M, Fekety R, Elmer GW, Greenberg RN: Recurrent *Clostridium difficile* disease: epidemiology and clinical characteristics. *Infect Control Hosp Epidemiol* 1999; 20: 43-50
 41. Fekety R: Guidelines for the diagnosis and management of *Clostridium difficile*-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol* 1997; 92: 739-750
 42. Tedesco FJ, Gordon D, Fortson WC: Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. *Am J Gastroenterol* 1985; 80: 867-868
 43. Silva J Jr: Update on pseudomembranous colitis. *West J Med* 1989; 151: 644-648
 44. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, et al.: A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA* 1994; 271: 1913-1918
 45. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C: *Saccharomyces boulardii* protease inhibits *Clostridium difficile* toxin A effects in the rat ileum. *Infect Immun* 1996; 64: 5225-5232